Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 15/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | SGK1 | O00141 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5835567 | 1.00 | UTS2R (0.66) | UTS2RLMNAMEN1KMT2AHTR2C | |
| SCHEMBL5835485 | 0.94 | UTS2R (0.64) | UTS2RLMNAMEN1KMT2AHTR2C | |
| SCHEMBL5835488 | 0.94 | UTS2R (0.64) | UTS2RLMNAMEN1KMT2AHTR2C | |
| SCHEMBL5842772 | 0.89 | UTS2R (0.66) | UTS2RHTR2CHTR2BSGK1 | |
| SCHEMBL8342125 | 0.89 | UTS2R (0.66) | UTS2RLMNAHTR2CHTR2B | |
| SCHEMBL5842767 | 0.89 | UTS2R (0.66) | UTS2RHTR2CHTR2BSGK1 | |
| SCHEMBL5835175 | 0.89 | UTS2R (0.67) | UTS2R | |
| SCHEMBL5835178 | 0.89 | UTS2R (0.67) | UTS2R | |
| SCHEMBL5741634 | 0.89 | UTS2R (0.61) | UTS2RHTR2CHTR2BSGK1 | |
| SCHEMBL5741822 | 0.89 | UTS2R (0.61) | UTS2RHTR2CHTR2BSGK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7026349-B2 | Sulfonamides | SMITHKLINE BEECHAM CORPORATION (US) | 2006-04-11 | — | — | US | claimed |
| US-20040152906-A1 | Sulfonamides | SHELL OIL COMPANY | 2004-08-05 | — | — | US | claimed |
| US-7026349-B2 | Sulfonamides | SMITHKLINE BEECHAM CORPORATION (US) | 2006-04-11 | — | — | US | disclosed |
| EP-1385507-A4 | SULFONAMIDES | SMITHKLINE BEECHAM CORP (US) | 2005-11-23 | — | — | EP | disclosed |
| US-20040152906-A1 | Sulfonamides | SHELL OIL COMPANY | 2004-08-05 | — | — | US | disclosed |
| EP-1385507-A1 | SULFONAMIDES | SmithKline Beecham Corporation (US) | 2004-02-04 | — | — | EP | disclosed |
| WO-2002089792-A1 | SULFONAMIDES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152906-A1 | Sulfonamides | UTS2R, PRSS2, STS | UTS2R 1/4885LMNA 3610/4885MEN1 3021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.